Kornimate/medical-research-clean huggingface dataset:
evaluating the use of educational videos in newly diagnosed patients in a medical oncology sarcoma clinic

Conditions: Sarcoma

Summary: this study aims to evaluate how sarcoma-specific educational videos improve patients' knowledge of their disease and treatment options before their first clinic appointment. participants will watch four educational videos before their first appointment with a medical oncologist. participants will be asked to complete surveys to assess their understanding of sarcoma and its treatment options before and after their first medical oncology clinic appointment.


Eligibility criteria:
inclusion criteria: 1. signed written and voluntary informed consent. 2. have histologically documented advanced metastatic sarcoma, or is a caregiver of a patient with histologically documented advanced metastatic sarcoma. 3. age ≥ 18 years. 4. have not received any previous systemic treatment for sarcoma, or is a caregiver of a sarcoma patient who has not received any previous systemic treatment for sarcoma. 5. willing/able to complete questionnaires. 6. able to read and write in english. exclusion criteria: 1. inability to provide informed consent. 2. previously seen by a medical oncologist for their sarcoma.

Keywords: education sarcoma
proton craniospinal radiation therapy vs. partial photon radiation therapy for leptomeningeal metastasis from solid tumors

Conditions: Leptomeningeal Metastases

Summary: the investigators are doing this study to find out whether proton craniospinal radiation therapy (proton csi) or partial photon radiation therapy is more effective at preventing leptomeningeal metastasis from worsening. the proton csi targets the entire space containing the csf, brain, and spinal fluid. the partial photon radiation therapy treats only areas where the patient is having symptoms, such as the entire brain or part of the spine. the investigators also want to find out if proton csi improves the symptoms patients may be experiencing because of the leptomeningeal metastasis. in addition, the investigators will compare the side effects of proton csi and partial photon therapy. patients undergoing proton beam rt will receive their treatment at the new york proton center in new york, ny. as part of the new york proton consortium, msk has contracted for its faculty to treat patients at the new york proton center. if it is unfeasible for patients to get treated at nypc, patients will have the decision to get treated at procure in summerset, nj.


Eligibility criteria:
inclusion criteria: * patient with solid tumor malignancy with leptomeningeal metastases established radiographically and/or through csf cytology * patients who are candidates for radiation therapy for the treatment of leptomeningeal metastases * patients of all ages * kps ≥ 60 for participants ≥ 16 years old, and lansky ≥ 60 for participants \< 16 years old * for adult patient, the patient/ legally authorized representative is able to provide informed consent. for pediatric patient, a parent is able to provide informed consent. * adequate bone marrow function: * hemoglobin \> 8g/dl * absolute neutrophil count \>1,000/mm * platelet count \> 100,000/mm * female subjects must either be of non-reproductive potential (i.e. pediatric patients, or postmenopausal by history \[≥ 60 years old, or with no menses for \>1 year without an alternative medical cause\], or history of hysterectomy, or history of bilateral tubal ligation, or history of bilateral oophorectomy) or must have a negative serum pregnancy test within 2 weeks prior to starting treatment. * patient at reproductive potential must agree to practice an effective contraceptive method. exclusion criteria: * patient with multiple, serious major neurologic deficits per physician/investigator assessment including encephalopathy * patient with extensive systemic disease and without reasonable systemic treatment options * patient who is unable to undergo mri brain and spine with gadolinium contrast * previous radiotherapy to the intended treatment site that precludes developing a treatment plan that respects normal tissue tolerances * pregnant or lactating women.

Keywords: proton craniospinal irradiation (csi) involved-field photon radiation therapy 20-117
canadian initiative to measure, predict and assess cancer treatment outcomes in patients treated with immuno-oncotherapeutics

Conditions: Carcinoma

Summary: the researchers doing this study are interested in doing the following: * biomarker research using fresh tumour tissue and normal blood cells, and if required, tumour tissue already collected. * bio-banking for use in future research using the collected tumour tissue / blood .

this study is being done to enable the collection and study of these samples. the results will also look at information on how participants with this type of cancer who received immunotherapy responded to treatment. bio-banking is the collection, storage, and use of human body samples and related health information for future research. it provides an important resource for health research locally, across canada, and around the world. the researchers doing the main study also are interested in storing any left-over tissue and/or blood samples that have not been used up for future research. the research that may be done on these samples in the future is unknown at this time.

Eligibility criteria:
inclusion criteria: * willingness to submit a blood sample for buffy-coat and at least one tumour biospecimen. * can-predict-io subgroup: provision of pre-treatment fresh tumour biopsy/resection tumour tissue for patients who will receive io treatment, in a specified list of io therapeutic trials currently active in cctg. or * can-pivot subgroup: provision of on-treatment or at-progression fresh tumour biopsy/resection tumour tissue for patients who have received io treatment, in a specified list of io therapeutic trials currently active in cctg. there are 2 can-pivot subgroups: primary resistance is defined as disease progression evident in initial on-treatment imaging or disease stability lasting less than six months. acquired resistance, on the other hand, manifests as disease progression subsequent to an initial partial or complete response or after a period of disease stability lasting six months or more. patients on adjuvant treatment, wit no evidence of disease (ned) by radiological assessment who develop disease (local recurrence or metastases) after or while on immunotherapy are included. * archived formalin fixed paraffin embedded (ffpe) blocks or slides would only be collected from patients who met can-impact-io study criteria and underwent fresh tumour biopsy/resection following consent but had a tumour specimen deemed insufficient for wgts. the ffpe sample may be used to provide an alternate source of tumour tissue for wgts in such cases. where local centre regulations prohibit submission of blocks of tumour tissue, a predetermined number of unstained slides of representative tumour tissue may substitute the tumour block. * participant consent for the can-impact-io study must be appropriately obtained in accordance with applicable local and regulatory requirements.
the application value of spectral ct in the accurate staging of colorectal cancer

Conditions: Colorectal Cancer

Summary: spectral ct was used to prospectively collect medical images and clinical data related to colorectal cancer, evaluate the effect of image quality in the diagnosis of colorectal cancer, and evaluate the application value in the accurate staging of colorectal cancer, so as to provide a more accurate clinical basis for diagnosis, promote the development of individualized treatment, and ultimately improve the prognosis of patients.


Eligibility criteria:
inclusion criteria: 1. undergo a contrast-enhanced quark spectral ct scan of the lower abdomen/pelvis within 1 week before treatment. 2. age \> 18 years. 3. patients suspected of having colorectal cancer. 4. patients who have signed the informed consent form. exclusion criteria: 1. severe cardiac, pulmonary, or renal insufficiency. 2. allergy to iodine-based contrast agents. 3. inability to cooperate with the ct examination. 4. poor image quality of the quark spectral ct scan. 5. women who are pregnant or breastfeeding.
study of genes and the environment in patients with prostate cancer residing in the east anglia, trent, or west midlands regions of the united kingdom

Conditions: Prostate Cancer

Summary: rationale: studying samples of blood from patients with cancer in the laboratory may help doctors learn more about changes that occur in dna and identify biomarkers related to cancer. purpose: this study is looking at genetic susceptibility and the interactions between genes and the environment in patients with prostate cancer.

objectives: * to obtain epidemiological information and biological material on a population-based series of prostate cancer cases. * to identify novel cancer susceptibility genes by comparison of genotype frequencies in cases with the corresponding frequencies in large control series. * to estimate the age and sex-specific risks associated with variants in predisposition genes. * to evaluate interactions between polymorphisms in predisposition genes and potential lifestyle risk factors. outline: this is a multicenter study. patients complete a detailed epidemiological questionnaire, including information on education, occupation, smoking habits, alcohol consumption, height, weight, family history of cancer, and past medical history. blood samples are collected from patients. dna is extracted from these blood samples and from samples collected from cancer-free control participants in mrec-search-control as well as from additional controls through the european prospective investigation of cancer (epic) study (a population based study of diet and health based in norfolk, east anglia). dna samples are analyzed for polymorphisms of low penetrance cancer susceptibility genes. in addition to the prostate cancer patients recruited for this study, patients with breast, ovarian, endometrial, colorectal, bladder, kidney, pancreatic, brain and esophageal cancer, malignant melanoma, and lymphoma cancer are recruited in the following related clinical trials: mrec-search-breast, mrec-search-ovarian, mrec-search-endometrial, mrec-search-colorectal, and mrec-search-cancer.

Eligibility criteria:
disease characteristics: * diagnosis of prostate cancer within the past 5 years * identified through the cancer registry serving any of the following geographic regions of the united kingdom: * east anglia * trent * west midlands patient characteristics: * identified by the patient's general practitioner as fit to contact for this study * no serious mental illness or retardation prior concurrent therapy: * not specified

Keywords: prostate cancer
covid-19 booster incentives

Conditions: Booster Message; Booster Message + Financial Incentive

Summary: the goal of this work is to understand whether small financial incentives and messaging can increase the take-up of covid-19 boosters among patients empaneled at a county public health system. the motivation for this work is the relatively low take-up of covid-19 boosters. in california, where our experiment is based, only 59% of the population has been boosted, with only 13% receiving the recommended bivalent booster (state of california, 2022).


Eligibility criteria:
inclusion criteria: 1. age: 18 and above 2. at least one covid-19 vaccination (primary series or monovalent booster) but no vaccination dose within the past 2-months. 3. active phone number or email exclusion criteria: 1. opt-out of health system messaging
neonatal brain waves after electrocoagulation

Conditions: Epilepsy

Summary: electrocoagulation effect of neonatal brain waves after cesarean section

electrocoagulation is used for bleeding control on usual basis in cesarean sections and other surgical procedures . we are planning to test the effect of electrocoagulation unipolar on neonatal brain waves compared with neonates that were exposed to bipolar electrocoagulation .bipolar electrocoagulation should have les of an effect because of it coagulates in a close ,closed electrical cycle .

Eligibility criteria:
inclusion criteria: * term normal newborn after normal pregnancy after elective cesarean section exclusion criteria: * any fetal or neonatal disease or condition that may affect brain waves

Keywords: electrocoagulation,pregnancy,brian waves
low dose cyclosporin and methotrexate therapy in diabetes

Conditions: Type 1 Diabetes Mellitus

Summary: the purpose of this study is to determine whether treatment with low dose cyclosporin and methotrexate can inhibit the development of new onset diabetes mellitus

objective: although high doses of cyclosporin (cyclo) inhibits the development of type 1 diabetes mellitus, its usefulness is limited by its toxicity. since methotrexate (mtx) and cyclo synergistically inhibit other disease processes, we hypothesized that low dose cyclo and mtx therapy could safely induce remission. research design and methods: in an open pilot study, insulin dose and glycemic control will be compared in children with new onset type 1 diabetes administered cyclo at 7.5 mg/kg/day for 6 weeks and then 4 mg/kg/day and mtx 5 mg/kg/day for one year with control children. after 6 weeks, doses were adjusted to maintain blood cyclo levels to 100-200 ng/ml.

Eligibility criteria:
inclusion criteria: * diagnosis of type1 diabetes mellitus and be obtaining insulin therapy for less than 4 weeks exclusion criteria: * ketoacidosis * body weight over 110% of ideal weight * condition where immunosuppression is contraindicated * abnormal liver or renal function tests

Keywords: type 1 diabetes mellitus cyclosporin methotrexate renal function
ct scan sizing for perceval sutureless valve

Conditions: Aortic Valve Regurgitation

Summary: the perceval sutureless aortic bioprosthesis is a bovine pericardium valve mounted in a nitinol stent that can be compressed and positioned in a valve delivery system. similarly, to transcatheter aortic valve implantation (tavi) devices, the anchoring and good sealing of the perceval bioprosthesis relies on oversizing by design of the nitinol stent compared with the native aortic annulus. with the advent of tavi, cardiac computed tomography (ct) has become the gold standard technique for measuring the aortic annulus in patients undergoing transcatheter procedures, and the ct-derived axial image of the aortic virtual basal ring (vbr) is considered as the reference for sizing by most of the manufacturers of transcatheter valves . interestingly, the vbr lies exactly on the plane passing through the nadir of the 3 aortic cusps, that is where, according to the instructions for use, a correctly positioned perceval valve should be deployed. vbr could then provide a good estimate of the annular dimension for the perceval pre-operative sizing.

recent evidence in tavi patients suggests that significant underexpansion or distortion of valved stents may be associated with altered leaflet function, leading to increased transprosthetic gradients and possibly predisposing to other negative outcomes such as valve thrombosis, low platelet counts, thromboembolic events, and early degeneration . moreover, there is evidence that excessive oversizing of the perceval valve is detrimental. the present study is aimed to investigate the relationship between the ct-derived measure of the annulus dimension and early hemodynamic and clinical outcomes in patients undergoing sutureless aortic valve replacement (avr) with the perceval sutureless aortic valve and define the perceval sizing chart based on preoperative ct-scan measurements.

Eligibility criteria:
inclusion criteria: 1. male and female subjects \> 18 years; 2. subjects willing to sign and date an informed consent for treatment of personal data; 3. subjects willing and able to comply with the follow up schedule of the protocol; 4. subjects with indication for aortic valve replacement on a tricuspid aortic valve; 5. subjects with possibly associated need for coronary revascularization. 6. subjects with ejection fraction ≥ 40% exclusion criteria: 1. male and female subjects ≤ 18 years; 2. subjects with bicuspid aortic valve 3. subjects with associated mitral valvulopathy or ascending aorta aneurysm 4. subjects with pure aortic insufficiency 5. subjects with ejection fraction \< 40% 6. subjects with acute myocardial infarction \< 30 gg 7. subjects with serum creatinine \> 2 mg/dl
clinical effect of lactobacillus reuteri in treatment of gingivitis

Conditions: Gingivitis

Summary: the aim of this randomized placebo- controlled clinical trials is to evaluate the effects of lactobacillus reuteri containing probiotic lozenges as an adjunct to scaling and root planning (srp). material and methods: thirty six gingivitis patients will be recruited and monitored clinically at baseline, 3 and 6 month after therapy. all patients will receive scaling and periodontal treatment and randomly will be assigned over an experimental (srp + probiotic, n=18) or control (srp+ placebo, n=18) group. the lozenges will be used once per day during 3 month.

gingivitis is the most prevalent worldwide periodontal disease, is characterized by inflammation of the tissues surrounding the tooth without causing periodontal attachment loss. preventive and / or therapeutic measures to facilitate or improve their control are therefore very important, much more if you consider that gingivitis and periodontitis are considered part of an ongoing inflammatory process. treatment of gingivitis, like that of all periodontal diseases has been based on the implementation of control measures personal and professional plaque. notwithstanding the foregoing, it has been reported that although mechanical therapy achieved significantly decrease the periodontopathogens, this may be only temporary since bacteria can recolonize the treated niches in the oral cavity. in this context, it has emerged as a new treatment strategy complementary use of probiotics such as lactobacillus reuteri, which possess anti-bacterial and anti-inflammatory properties. generally speaking, probiotics would promote health by competitive exclusion of some or positive pathogenic bacteria. objective: to evaluate the effect of the administration of lactobacillus reuteri as an adjunct to conventional periodontal therapy in adolescent and young adult patients with gingivitis. methodology: a randomized double-blind clinical trial to evaluate the effect of probiotic lozenges lactobacillus rhamnosus as an adjunct to conventional periodontal treatment of patients with gingivitis will be performed. expected results: statistically significant decrease in bleeding and gingival index in the experimental group compared with the control.

Eligibility criteria:
inclusion criteria: * diagnosis of gingivitis * gingival index \> 1.5 (\> 10 % of sites examined) * bleeding index \> 10 % sites surveyed * probing depth \< 4 mm * systemically healthy (except for the presence of gingivitis) * patients who have not received periodontal treatment before the test and no intake of medicines such antibiotic and/ or anti-inflammatory in the last 3 months prior to the start of the study exclusion criteria: * patient who develop systemic disease during the study * patient who have to ingest antibiotic/ or anti-inflammatories during the study * if you are a woman becomes pregnant during the study

Keywords: gingivitis probiotic non- surgical treatment
extensively hydrolyzed infant formula in infants and children with cow's milk allergy

Conditions: Cow's Milk Allergy

Summary: this is a multi-center, randomized, double-blind, placebo-controlled food challenge to be conducted in infants or children with confirmed ige-mediated cow's milk allergy (cma), followed by a 7-day open feeding of the experimental formula.


Eligibility criteria:
inclusion criteria: * participant has a physician diagnosis of ige-mediated cow's milk allergy (cma) based on a clinical history of a reaction resulting in characteristic immediate hypersensitivity symptoms within 2 hours of oral exposure or immediate hypersensitivity symptoms according to physician's observation * participant is willing to undergo confirmatory testing or must have had at least one of the following within 6 months of enrollment: 1. documentation of milk-specific serum ige \>15 kiua/l or \> 5 kiua/l if younger than 1 year. 2. documented cow's milk skin prick test mean wheal \>10mm 3. physician-supervised oral food challenge that elicited immediate, objective, allergic symptoms. * participant agrees to stop oral steroid use within 14 days and antihistamine use within 7 days of confirmation of diagnosis and food challenges. * participant had followed a strict cow's milk protein-free diet prior to enrollment. * parent(s) confirm their intention not to administer any products containing cow's milk protein during the study. * participant's parent(s) has voluntarily signed and dated an informed consent form (icf), approved by an independent ethics committee/institutional review board (iec/irb) and provided health insurance portability and accountability act (hipaa) (or other applicable privacy regulation) authorization prior to any participation in the study. exclusion criteria: * participant is exclusively breastfed at the time of enrollment. * participant is consuming an amino acid-based formula due to failure on an extensively hydrolyzed formula. * significant chronic medical diseases including major chromosomal or congenital anomalies, gastrointestinal diseases or abnormalities other than cma, immunodeficiencies, unstable asthma, asthma treated with biologics (omalizumab or other monoclonal antibody), fpies, eosinophilic esophagitis, and severe uncontrolled eczema. * previous severe anaphylactic reaction to cow's milk within the last two years. * an adverse medical history or current condition that is thought by the investigator to have potential for effects on tolerance or the hypoallergenicity test. * participant has an allergy or intolerance to any ingredient in the study product, as reported by the parent. * participant is routinely consuming baked milk products.
pilot evaluation of the jhi platform

Conditions: Coronary Artery Disease

Summary: the main purpose of this pilot study is to evaluate an impact of jhi cr platform on patient referral, recruitment and retention rates and overall patient satisfaction in cardiovascular rehabilitation programs at the hfhs.


Eligibility criteria:
inclusion criteria: * men and women age 18 years old (inclusive) and older * recent hospitalization at hfhs main campus hospital with one of the following diagnosis * stable angina with medical management * myocardial infarction (mi)/acute coronary syndrome * percutaneous coronary intervention (pci) * coronary artery bypass graft (cabg) surgery * heart valve surgical repair or replacement * patients must be attending outpatient cr program at the hfhs detroit location. * willingness to participate in the study and follow study requirements * willingness to respond to several surveys at the baseline and periodically during the study exclusion criteria: * active substance abuse per medical record * unstable psychiatric condition * inability to exercise * unstable medical condition that would prevent safe and regular exercise training * uncorrected severe aortic stenosis or severe mitral stenosis * inpatient referring physician feels that exercise in contra-indicated due to safety reasons or is ill advised due to other patient specific factors * lvad, heart transplant. although these patients qualify for cr, hfhs is not recruiting them due to difficulty in coordinating with surgical patients and their providers. in addition, there may also be surgical issues (infection, wound dehiscence, bone healing etc) that may reasonably interfere with exercise.

Keywords: coronary artery disease cardiac rehabilitation